Telitacicept safely and effectively eased disease activity in adults with primary Sjögren’s disease, according to data from a now-complete Phase 3 clinical trial conducted in China. Because the trial met its primary goal, developer Remegen plans to ask China’s regulator, the Center for Drug Evaluation of the National Medical Products Administration, to approve the drug, according […] The post Telitacicept shows promise for primary Sjögren’s in Phase 3 trial appeared first on Sjogre...| Sjogren's Disease News – The Web's Daily Resource for Sjogren's Disease News
Treatment with nipocalimab in gMG patients led to significant reductions in disease severity, per top-line data from a pivotal Phase 3 trial.| Myasthenia Gravis News
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.| Alzheimer's News Today